Clinical Trials | December 31, 2025
GenSight Biologics gets early access nod for candidate gene therapy in Israel
Applications include detailed scientific rationale and supporting clinical evidence
Applications include detailed scientific rationale and supporting clinical evidence
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Subscribe To Our Newsletter & Stay Updated
